PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.

Slides:



Advertisements
Similar presentations
PRINCIPLES OF A CALIBRATION MANAGEMENT SYSTEM
Advertisements

Chemometric Working Group Recommendations and Summary of Discussion.
Statistical Approaches to Addressing the Requirements of the New FDA Process Validation Guidance for Small Molecules 1 Jason Marlin, MS/T Statistics, Eli.
Stability data required by WHO-PQP Mercy Acquaye.
ISO 9001 : 2000.
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
Batch Reworking and Reprocessing
Mitigating Risk of Out-of-Specification Results During Stability Testing of Biopharmaceutical Products Jeff Gardner Principal Consultant 36 th Annual Midwest.
World Health Organization
World Health Organization
SAE AS9100 Quality Systems - Aerospace Model for Quality Assurance
Quality control of raw materials In-process control
MANUFACTURING OF API AND INTERMEDIATES
Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.
Short Course on Introduction to Meteorological Instrumentation and Observations Techniques QA and QC Procedures Short Course on Introduction to Meteorological.
By: Muhammad Naeem Quality Assurance and Regulatory Manager
COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
VALIDATION OF RAW MATERIALS
QUALITY CONTROL OF PHYSICO-Chemical METHODS Introduction :Validation توثيق المصدوقية.
Guidance for Industry Process Validation: General Principles and Practices Dr. Mark Tucker, F. Hoffman-La Roche, Ltd.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Radiopharmaceutical Production
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
World Health Organization
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Introduction to ISO New and modified requirements.
Rocky Mountain RAPS Process Validation Presentation 6/7/06 By Clay Anselmo.
1 Manufacturing Processes and Validation for Next Generation Implants.
VALIDATION METHODOLOGY
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
ISO 9001:2000 QUALITY MANAGEMENT SYSTEM REQUIREMENTS
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
MB RESEARCH LABORATORIES Increased Regulatory Vigilance with respect to GLP Test Article Characterization George L. DeGeorge, Ph.D., DABT MB Research Laboratories.
1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.
Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Important informations
Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.
Overview of FDA's Regulatory Framework for PET Drugs
Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.
Molecule-to-Market-Place Quality
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.
Comparability Protocols Lore Fields MT(ASCP)SBB Consumer Safety Officer DBA/OBRR/CBER September 16, 2009.
Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
The world leader in serving science Validation and Qualification Overview Mike Garry Software Product Manager Spectroscopy Software Platform Team.
Module 2Slide 1 of 26 WHO - EDM Quality Management Basic Principles of GMP Part One.
Process Analytical Technologies (PAT) Sub-Committee Report ACPS Meeting October 21, 2002 Tom Layloff, Ph.D.
Process Analytical Technologies (PATs), Applications and Benefits Working Group.
Wenclawiak, B.: Fit for Purpose – A Customers View© Springer-Verlag Berlin Heidelberg 2003 In: Wenclawiak, Koch, Hadjicostas (eds.) Quality Assurance in.
Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.
FDA PAT Sub-Committee of Advisory Committee for Pharmaceutical Sciences June 12-13, 2002; Gaithersburg, MD Regulatory Challenges: Post-Approval PAT Applications.
Topic #2: Quality by Design and Pharmaceutical Equivalence Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Science Center for Drug Evaluation and Research.
1 Manufacturing Processes and Validation for Next Generation Implants.
Product & Process Working Group February 26, 2002.
SEMINAR ON PRESENTED BY BRAHMABHATT BANSARI K. M. PHARM PART DEPARTMENT OF PHARMACEUTICS AND PHARMACEUTICAL TECHNOLGY L. M. COLLEGE OF PHARMACY.
1. Our Presentation Topic: Importance Of Validation & Qualification In Pharmaceutical Industries Presented By: Md. Tanjir Islam (Group C) 2.
TGDC Meeting, Jan 2011 VVSG 2.0 and Beyond: Usability and Accessibility Issues, Gaps, and Performance Tests Sharon Laskowski, PhD National Institute of.
GCP (GOOD CLINICAL PRACTISE)
means to “TO CHECK OR PROVE THE VALIDITY OF” According to FDA – “ The goal of validation is to establish a documented evidence which provides a high degree.
Strategy for IVD product development, validation and commercialization
Uncontrolled variation is the enemy of quality
WHO Technical Report Series, No. 953, 2009
Food Production Systems
Quality Systems in a Production Facility
This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download,
METHOD VALIDATION: AN ESSENTIAL COMPONENT OF THE MEASUREMENT PROCESS
Presentation transcript:

PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002

PAT Validation Working Group Process Analytical Technologies Systems for the analysis and control of manufacturing processes based on timely measurements during processing of critical quality parameters and performance attributes of raw and in- process materials and processes, to assure acceptable end-product quality at the completion of the process. Definition of validation Three lots and done? Follow the C in CGMP. The science continues to move forward. In many cases, existing validation processes are adequate for PAT Internal buy-in may be most difficult. Case studies (examples) will help educate inside the company

PAT Validation Working Group PAT Validation Background - Existing validated measurements invariably correlate poorly with process performance - Univariate measurements used to infer compliance of multivariate dynamic systems - Measure what we can measure, not what needs to be measured - Measurement has not been seen as process related - Measurement needs to respond to process need over the product life cycle - Need to understand the process - Recognize that the conventional approach to validation might be limiting

PAT Validation Working Group Understand the Process - Break down into unit operations - Assess risk potential for each unit individually and collectively using techniques, e.g. experimental design - Design systems to manage risk Univariate measurement Multivariate systems - Develop systems - Establish proof of concept - Challenge validation Objective - confirm processes and measurement validity in “real” time across life cycle

PAT Validation Working Group Validation Postulates 1. Validation Protocols will be different for new products associated with well-designed understood manufacturing processes and existing products where PAT is applied retrospectively 2. The validation plan will reflect the total system design concept since an RTQC/QA manufacturing process, statistically based, essentially revalidates itself on every manufacturing batch 3. The rationale for model validation incorporating pass/fail criteria must be clearly defined thereby establishing the authenticity of predictions in routine manufacturing and ensuring compliance

PAT Validation Working Group A Checklist for Sensor and Chemometrics Validation Sensor validation Software validation including multivariate algorithms Sensor calibration and calibration transfer validation Process monitoring protocol (batch vs.continuous) Process modeling (fundamental process) Process control protocol Data management and storage protocol

PAT Validation Working Group A Checklist of Targets for Validation Method Types Primary method (no other method required, e.g., endpoint detection) Secondary Method (requires primary method to validate) Analyte Types Direct measure (e.g., active ingredient) Indirect measure (e.g., dissolution) Virtual measure (e.g. customer satisfaction or quality index value) Dimensionality univariate multivariate

PAT Validation Working Group PAT Implementation Questions What information is needed and why? Where are the appropriate measurement points? When (how often) are the measurements needed? How is PAT provided information to be used? Who will interpret this information? (i.e., who receives and interprets?)

PAT Validation Working Group It is possible to define three distinct ways of analyzing unit operations and releasing products that are being developed and manufactured. Condition 1: This is generally the current operating scenario. Product is manufactured according to fixed process conditions set during development and confirmed during initial process and product validation. Release is conducted by physical and chemical testing subsequent to manufacture. Condition 2: Product is manufactured according to process conditions that have been shown during development and manufacturing to infer product performance and is confirmed during initial process and product validation. Relationships are developed and confirmed with physical and chemical testing subsequent to manufacturing runs. Release is conducted by review of process conditions during each batch manufacture.

PAT Validation Working Group Condition 3: Product is manufactured according to process conditions that are responding to direct measurement of in-process product quality or unit dosage forms as they are being manufactured. Relationships are developed between process and product performance that are optimized and bounded by data obtained in development and manufacturing runs. Release is conducted by data collected from in-process product or each dosage form during manufacture. Release specification form and validation criteria can be defined for each condition based on the nature of their release.

PAT Validation Working Group Questions to Move Forward on Improving PAT Validation Should there be a difference in expectations between developmental product released for PI, PII, PIII than for routine manufactured lots? Current validation practice requires each unit operation in a manufacturing process to be tested individually. Is it more appropriate to design ‘validation testing’ around a total systems approach that includes multiple unit operations? If so, what level of process and product understanding is required during design, development, scale- up and manufacture? Could and should there be official designations for products and processes that are inherently capable of being appropriately measured and controlled that would allow for predicting product release characteristics?

PAT Validation Working Group Content Recommendations for Guidance Document 1. Suitable for intended purpose 2. General validation criteria 3. References to existing guidance documents (ICH Q2: a and b Analytical Validation, Q6: a and b, Specifications, FDA Analytical Procedures and Methods Validation) 4. Research exemption 5. OOT/OOS 6. Encourage use of PAT. FDA should have a mechanism to institute these new technologies and methods

PAT Validation Working Group Ex. 1. How to handle validation of PAT method for a process monitoring or set-up parameter that will be used for learning or decision-making? As for other analytical methods: use scientific judgement to develop appropriate validation and long-term maintenance protocol. New parameters appear that need to be measured during a product life cycle, especially for research purposes like process optimization (the “safe harbor” issue) Example PAT Method Validation Issues

PAT Validation Working Group Ex. 2. A validated laboratory method exists for a regulatory parameter across an NDA range. How do we replace this with a PAT method? Validate PAT method, including long-term maintenance program to monitor performance (both instrument function and calibration model), and submit supplemental regulatory method change documentation to FDA. PAT method should correlate to validated lab method as appropriate for intended use, and should provide the same or increased assurance of identity, strength, quality, purity, or potency of the material being tested as the analytical procedure described in the approved application.

PAT Validation Working Group Ex. 3. PAT Method is used in pilot plant for process monitoring and development of a new drug. When and how to validate? Steps: 1. Calibrate PAT method for use in pilot plant 2. Calibrate and validate internally for factory process monitoring 3. Validate and file method with FDA if it ends up as a regulatory parameter.

PAT Validation Working Group Ex. 4. PAT method has been validated but probe has a mechanical problem or sampling problem (e.g., window fouling). An equivalent validated laboratory method exists. State up front in internal process control documentation the preferred method and circumstances in which the equivalent method could be used.

PAT Validation Working Group Ex. 5. A PAT method can only be calibrated during factory processing. Process is optimally run within an operating range narrower than the fully validated range, so it is not always possible to easily calibrate at the ends of the range. Validate PAT method and use hybrid approach. Specify the validated range for the PAT method. When operating outside of this range, must use laboratory method until PAT method is revalidated to include the new range.

PAT Validation Working Group Ex. 6. PAT method is validated for typical batches over a fixed range. Want to expand calibration range/incorporate process change or reworks. Include provision in PAT method validation for controlled updating of calibration model and revalidating as needed

PAT Validation Working Group Ex. 7. Accuracy of PAT method is different than previously validated laboratory method. Validate analytical method to the accuracy required BY THE PROCESS rather than to the limits of the method. A long-term maintenance program to monitor performance (both instrument function and calibration model) should be in place.